Fairmount Just Sold $400 Million in Spyre Therapeutics
Fairmount Healthcare Fund II sold $399.7M in Spyre common stock via Series B preferred conversion at $85.31. Direct common zeroed. 346,045 Series A preferred shares convertible into 13.8M common remain at the 9.99% cap.
π΄ Insider Activity Score: 99/100
Fairmount Healthcare Fund II L.P., operating under a director-by-deputization compliance mandate through managing member Tomas Kiselak's board seat, filed a Form 4 on June 23, 2026 disclosing the sale of 4,684,781 common shares at a locked execution price of $85.31 for approximately $399,658,667 β funded in part through the zero-cost conversion of 16,667 Series B Preferred shares into 666,680 common shares to complete the broker block. The distribution zeroed Fairmount's direct common share balance entirely. The fund retains 346,045 Series A Preferred shares convertible into approximately 13,842,000 common shares β a position deliberately held at the fund's strict 9.99% regulatory beneficial ownership cap. The $400 million is the harvest. The 13.8 million convertible equivalents are the structural anchor that the 9.99% cap is preserving.
The Director-by-Deputization Framework
Kiselak's board seat creates the Section 16 reporting obligation that governs this filing β the same governance proxy structure this series documented across Egon Durban's Silver Lake Dell distributions, Peter Feld's Starboard Qorvo trim, and Reid Hoffman's Greylock Aurora disclosures.
Fairmount Healthcare Fund II is not a passive financial allocator making a portfolio rebalancing decision. It is a dedicated healthcare specialist fund whose managing member holds a board seat at a clinical-stage company β giving Fairmount the most complete available picture of Spyre's autoimmune pipeline, clinical data quality, and regulatory pathway clarity before executing a $400 million distribution at $85.31.
A healthcare specialist fund with board-level clinical intelligence executing a $400 million locked-price block has made a fund lifecycle capital return decision at the specific valuation that its clinical thesis has delivered β not a real-time panic exit, but a structured harvest at the price the autoimmune pipeline's development has earned.
The Series B Preferred Conversion: Building the Block
The zero-cost conversion of 16,667 Series B Preferred shares into 666,680 common shares is the specific structural mechanism that completed the 4,684,781-share broker block β the preferred-to-common conversion providing the final common share inventory required to reach the full block size at the locked $85.31 price.
The conversion at zero cost reflects the standard preferred-to-common conversion mechanics this series has documented across multiple dual-class and preferred equity events: preferred shares converting to common at the defined ratio with no incremental cash cost, with the entire execution price representing proceeds on shares whose preferred basis was established at an earlier stage of Spyre's financing history.
The 16,667 Series B shares converting to 666,680 common β a 40:1 conversion ratio β confirms the specific preferred instrument design: high-ratio conversion preferred equity used in clinical-stage biotech financing rounds where the preferred price per share is substantially higher than the common equivalent but the common conversion pool is correspondingly larger.
The Zero Direct Common Balance: What "Emptied" Means Analytically
The complete elimination of Fairmount's direct common share balance following the distribution requires precise analytical treatment β because the direct common zeroing is the headline that scanner infrastructure will generate maximum alarm around, while the 346,045 Series A Preferred shares convertible into 13.8 million common equivalents represent the structural position that survived the distribution entirely.
A fund that zeros its direct common balance while retaining preferred equity convertible into 13.8 million common shares has not exited Spyre. It has converted its liquid common exposure into realized proceeds while preserving the structural preferred position that its 9.99% regulatory cap is managing. The direct common zero is the output of a block sale that converted all available common inventory β including the Series B conversion β to cash. The 346,045 Series A shares are the position that the distribution was specifically designed not to touch.
The 9.99% Regulatory Cap: The Structural Preservation Mechanism
The 9.99% beneficial ownership cap is the specific regulatory constraint that explains both why Fairmount retains 346,045 Series A Preferred shares and why those shares are convertible into approximately 13.8 million common equivalents rather than already converted.
Beneficial ownership caps β common in healthcare fund investment agreements and preferred equity terms β limit a fund's total convertible beneficial ownership to a defined percentage of the company's outstanding shares. At 9.99%, Fairmount's Series A Preferred is deliberately structured to stay just below the threshold that would trigger additional regulatory reporting obligations, HSR Act filing requirements, or other beneficial ownership-linked compliance events.
The 13.8 million common equivalent shares represented by the 346,045 Series A Preferred are not being converted because conversion would push Fairmount above the 9.99% cap β the specific regulatory ceiling that the preferred's unconverted structure is preserving. When Spyre's outstanding share count grows sufficiently β through new equity issuances, employee stock plan exercises, or other dilutive events β the 9.99% cap's absolute share equivalent rises, potentially creating the headroom that would allow conversion without triggering the cap.
The 9.99% cap is not a limitation on Fairmount's economic exposure. It is the regulatory engineering that preserves a dominant unconverted preferred position while allowing the common inventory to be fully harvested.
The $85.31 Locked Price: Autoimmune Pipeline Valuation
The locked $85.31 execution price across 4,684,781 shares β a single negotiated block price rather than a fragmented open-market average β reflects the broker's assessment of the institutional demand available to absorb a $400 million Spyre Therapeutics block at a specific clearing price.
Spyre Therapeutics develops next-generation antibody therapies for autoimmune and inflammatory diseases β a therapeutic category whose clinical and commercial momentum has driven significant institutional attention as the autoimmune biologics market continues expanding across inflammatory bowel disease, rheumatology, and related indications. The $85.31 block price reflects the institutional market's current valuation of Spyre's autoimmune pipeline at the specific clinical stage and competitive positioning that Fairmount's board-level visibility has assessed across its investment tenure.
A healthcare specialist fund with managing member board access executing a $400 million block at $85.31 has determined that this price represents the appropriate capital return harvest point β the valuation at which the clinical thesis has delivered the maximum near-term institutional liquidity for a fund returning capital to its LP base.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation antibody therapies for autoimmune and inflammatory diseases, with a pipeline targeting conditions including inflammatory bowel disease and related indications. Fairmount Healthcare Fund II L.P. distributed 4,684,781 common shares at $85.31 for approximately $399,658,667, zeroing its direct common balance while retaining 346,045 Series A Preferred shares convertible into approximately 13,842,000 common equivalents β held deliberately at the fund's 9.99% regulatory beneficial ownership cap. Managing member Tomas Kiselak retains his board seat following the distribution. Spyre Therapeutics trades on the Nasdaq under the ticker SYRE.
How to Think About This
Fairmount's $400 million Spyre block scores 99/100 β the maximum sell-side score this series assigns, reflecting the specific convergence of a nine-figure healthcare specialist fund distribution, a Series B preferred conversion completing the broker block, the complete zeroing of the direct common position, and the deliberate preservation of a 13.8 million convertible equivalent Series A Preferred stake at the 9.99% regulatory cap.
The 99/100 is the alarm-management score for the largest single-filing cash realization this series has documented at a clinical-stage biotech β $399.7 million at a locked price through a dedicated healthcare fund whose managing member board seat gives the distribution the most informed possible clinical validation context.
The direct common zero is the scanner's input. The 346,045 Series A Preferred shares convertible into 13.8 million common equivalents β deliberately preserved at the 9.99% cap β are the analytical output. Fairmount did not exit Spyre. It harvested the common inventory while engineering the preferred structure to survive the distribution intact, positioned exactly at the regulatory ceiling that preserves maximum future optionality.
The block sold $400 million at $85.31. The 9.99% cap protected 13.8 million convertible equivalents. The board seat stayed.
Three things happened simultaneously. Only one of them generated the scanner alert.